Exelixis Inc (NASDAQ:EXEL) — Market Cap & Net Worth
Market Cap & Net Worth: Exelixis Inc (EXEL)
Exelixis Inc (NASDAQ:EXEL) has a market capitalization of $12.17 Billion ($12.17 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1924 globally and #724 in its home market, demonstrating a -4.94% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Exelixis Inc's stock price $56.21 by its total outstanding shares 259708689 (259.71 Million). Also see balance sheet size of Exelixis Inc for a full breakdown of the balance sheet.
Exelixis Inc Market Cap History: 2015 to 2026
Exelixis Inc's market capitalization history from 2015 to 2026. Data shows growth from $1.46 Billion to $14.60 Billion (23.14% CAGR). Also see Exelixis Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Exelixis Inc is a constituent of 5 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$1.06 Trillion | 1.15% | #19 of 30 |
|
NASDAQ Health Care
IXHC
|
$2.68 Trillion | 0.46% | #36 of 976 |
|
NASDAQ Composite
IXIC
|
$41.94 Trillion | 0.03% | #220 of 3165 |
|
S&P Midcap 400
MID
|
$3.42 Trillion | 0.38% | #74 of 401 |
|
NASDAQ Biotechnology
NBI
|
$1.89 Trillion | 0.64% | #27 of 263 |
Weight: Exelixis Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Exelixis Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Exelixis Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Exelixis Inc share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
4.91x
Exelixis Inc's market cap is 4.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
14.55x
Exelixis Inc's market cap is 14.55 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.87 Billion | $191.45 Million | -$70.22 Million | 20.23x | N/A |
| 2017 | $7.90 Billion | $452.48 Million | $154.23 Million | 17.45x | 51.19x |
| 2018 | $5.11 Billion | $853.83 Million | $690.07 Million | 5.98x | 7.40x |
| 2019 | $4.58 Billion | $967.77 Million | $321.01 Million | 4.73x | 14.26x |
| 2020 | $5.21 Billion | $987.54 Million | $111.78 Million | 5.28x | 46.63x |
| 2021 | $4.75 Billion | $1.43 Billion | $231.06 Million | 3.31x | 20.55x |
| 2022 | $4.17 Billion | $1.61 Billion | $182.28 Million | 2.59x | 22.85x |
| 2023 | $6.23 Billion | $1.83 Billion | $207.76 Million | 3.40x | 29.99x |
| 2024 | $8.65 Billion | $2.17 Billion | $521.27 Million | 3.99x | 16.59x |
| 2025 | $11.38 Billion | $2.32 Billion | $782.57 Million | 4.91x | 14.55x |
Competitor Companies of EXEL by Market Capitalization
Companies near Exelixis Inc in the global market cap rankings as of September 16, 2026. Review EXEL tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Exelixis Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #338 globally with a market cap of $80.28 Billion USD.
- CSL Ltd (AU:CSL): Ranked #463 globally with a market cap of $58.90 Billion USD ( AU$83.24 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $519.51 |
| #338 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.28 Billion | $793.74 |
| #463 | CSL Ltd | AU:CSL | $58.90 Billion | AU$171.57 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $146.69 |
Exelixis Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Exelixis Inc's market cap moved from $1.46 Billion to $ 14.60 Billion, with a yearly change of 23.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $14.60 Billion | +28.25% |
| 2025 | $11.38 Billion | +31.62% |
| 2024 | $8.65 Billion | +38.81% |
| 2023 | $6.23 Billion | +49.56% |
| 2022 | $4.17 Billion | -12.25% |
| 2021 | $4.75 Billion | -8.92% |
| 2020 | $5.21 Billion | +13.90% |
| 2019 | $4.58 Billion | -10.42% |
| 2018 | $5.11 Billion | -35.30% |
| 2017 | $7.90 Billion | +103.89% |
| 2016 | $3.87 Billion | +164.36% |
| 2015 | $1.46 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of Exelixis Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.17 Billion USD |
| MoneyControl | $12.17 Billion USD |
| MarketWatch | $12.17 Billion USD |
| marketcap.company | $12.17 Billion USD |
| Reuters | $12.17 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Exelixis Inc
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyro… Read more